1-4 of 4
David Kahn
Close
Sort by
Journal Articles

A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of Sgr-1505 As Monotherapy in Subjects with Mature B-Cell Malignancies

Adam Olszewski, David Kahn, Brian Yoo, Joanne BL Tan, Vipul K Gupta, Edgar Schuck, Zhe Nie, Goran Krilov, D. Hamish Wright, Daniel Weiss, Jean Lachowicz, Karen Akinsanya, Wu Yin
Journal: Blood
Blood (2023) 142 (Supplement 1): 3102.
https://doi.org/10.1182/blood-2023-182838
Published: 2023
Journal Articles

Clonotypic Bone Marrow-Derived Endothelial Progenitor Cells in Multiple Myeloma.

Marc J. Braunstein, MD, PhD, Daniel R. Carrasco, MD,PhD, David Kahn, MD, Kumar Sukhdeo, PhD, Alexei Protopopov, PhD, Yunyu Zhang, Kenneth C. Anderson, MD, Olcay Batuman, MD
Journal: Blood
Blood (2006) 108 (11): 3497.
https://doi.org/10.1182/blood.V108.11.3497.3497
Published: 2006
Journal Articles

Treatment of Newly Diagnosed, Inner-City Multiple Myeloma Patients with Zoledronate, Dexamethasone, and Low-Dose Thalidomide: A Phase II Trial.

Uwe Klueppelberg, MD, PhD, Eric L.P. Smith, PhD, Marc J. Braunstein, MD, PhD candidate, David Kahn, MD, Olcay A. Batuman, MD
Journal: Blood
Blood (2006) 108 (11): 5124.
https://doi.org/10.1182/blood.V108.11.5124.5124
Published: 2006
Journal Articles

Treatment of Newly Diagnosed, Inner-City Multiple Myeloma Patients with Low-Dose Thalidomide in Combination with Dexamethasone and Zoledronate: A Phase II Trial.

Uwe Klueppelberg, MD, PhD, Iuliana Shapira, MD, Eric Smith, PhD, Marc Braunstein, BS, David Kahn, MD, Yury Pertsovsky, Olcay Batuman, MD
Journal: Blood
Blood (2005) 106 (11): 5180.
https://doi.org/10.1182/blood.V106.11.5180.5180
Published: 2005